Savara Inc公司面临一项诉讼,指控其药物申请中隐藏了缺陷,导致在林业发展局拒绝后库存下降31.7%。 Savara Inc. faces a lawsuit for allegedly hiding flaws in its drug application, leading to a 31.7% stock drop after the FDA rejected it.

对Savara Inc.(SVRA)提起了证券集团诉讼,指控该公司在2024年3月7日至2025年5月23日期间误导投资者,没有披露其MOLBREEVI药物的生物许可证申请中的重大缺陷,包括化学、制造和控制数据不足。 A securities class action lawsuit has been filed against Savara Inc. (SVRA) alleging that the company misled investors from March 7, 2024, to May 23, 2025, by failing to disclose critical flaws in its MOLBREEVI drug’s Biologics License Application, including insufficient chemistry, manufacturing, and controls data. 美国食品和药物管理局于2025年5月27日发布了一封拒绝提交的信,理由是不完整,导致萨瓦拉的股价下跌31.69%,至1.94美元. The FDA issued a refusal-to-file letter on May 27, 2025, citing incompleteness, causing Savara’s stock to drop 31.69% to $1.94. 2025年11月7日之前,在班级期间损失钱财的投资者可申请领导诉讼。 Investors who lost money during the class period may apply to lead the lawsuit by November 7, 2025. 该案尚未结案,没有结果得到保证。 The case is pending, and no outcome is guaranteed.